Quantcast

Latest placebo Stories

2014-10-01 08:33:14

FLORHAM PARK, N.J., Oct. 1, 2014 /PRNewswire/ -- Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from clinical trials of ospemifene (available in the U.S. marketplace as Osphena(®)) at the 25(th) Annual Meeting of The North American Menopause Society (NAMS) in Washington, DC on October 15-18, 2014. Osphena(®) (ospemifene) is approved for the treatment of moderate to severe dyspareunia, a symptom of...

2014-09-19 08:25:54

CORAL SPRINGS, Florida, September 19, 2014 /PRNewswire/ -- BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for...

2014-09-17 08:29:26

- Phase 2 Clinical Results Show Positive Trends in Slowing Advancement of Disease - PALO ALTO, Calif., Sept. 17, 2014 /PRNewswire/ -- Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy results of the Company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) are being highlighted today in an oral presentation at the inaugural Summit of the ALS Research Group, being held in Bloomington,...

2014-09-15 08:29:32

- Significantly Improved Agitation in 220-Patient 10-week Study - ALISO VIEJO, Calif., Sept. 15, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease. Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression...

2014-09-14 20:20:15

Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND OAKS, Calif., Sept. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18(th)...

2014-09-10 16:26:51

Approval based on improved overall survival, delayed time to radiographic progression and an overall positive benefit-risk profile TOKYO and SAN FRANCISCO, Sept. 10, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for the use of XTANDI(®) (enzalutamide) capsules to treat patients with metastatic castration-resistant prostate cancer (CRPC). This new approved...

2014-09-09 08:30:47

AT-003 Demonstrates Greater Pain Control Over Time Compared to Placebo in Client-Owned Dogs KANSAS CITY, Kan., Sept. 9, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced positive results from its pilot field study of its Bupivacaine Extended-Release Injectable Suspension (AT-003) for managing post-operative pain in...

2014-09-02 08:31:53

- Potential Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) in Men and Women Granted Priority Review Status - DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D)....

2014-08-25 08:27:22

ENGLEWOOD, Colo., Aug. 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is issuing this response to the most commonly asked questions in regards to the STEP study and clarify its plan for moving forward with Ampion(TM) for osteoarthritis of the knee. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Letter to Ampio Shareholders from Michael Macaluso, Chairman & CEO and David Bar-Or, MD, Chief Scientific Officer The STEP study of Ampion(TM)...

2014-08-21 20:22:34

LYNBROOK, N.Y., Aug. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced positive, statistically significant results from a randomized, double-blind Phase 2a study of CCH for the potential treatment of cellulite, or edematous fibrosclerotic panniculopathy. The results...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related